Psychedelic drug

PSYC’s Psychedelic Spotlight Closes Strong Q1 With New KPI Records in March

Retrieved on: 
Wednesday, April 5, 2023
KPI, OTC Markets Group, Policy, Google Analytics, Multimedia, Research, Burn, Psychedelic drug, Management, Growth, News, KPI-driven code analysis, Nightclub

These healthy statical-performing months come just two months after a series of strategic updates to its operating model implemented by Management.

Key Points: 
  • These healthy statical-performing months come just two months after a series of strategic updates to its operating model implemented by Management.
  • “From our perspective, much of this relies heavily on the establishment of Psychedelic Spotlight into the premiere news, information, and resource authority for all things psychedelics.
  • "Psychedelic Spotlight realized significant organic growth as a result of our lean, efficient team executing their strategies in real-time and doing more with less.
  • Psychedelic Spotlight continues to present psychedelic culture, policy, research, and industry news in a captivating manner without sacrificing integrity.

Cannabis Science Conference Announces Canna Boot Camp Location, Pre-Conference Educational Off-Site Workshop on April 19

Retrieved on: 
Monday, April 3, 2023
Psilocybin, Timeline of cannabis laws in the United States, Education, CSC, OR, Sweet spot, Food, QA/QC, Veteran, Cannabinoid, Sale, DO, Institute of Analytical Sciences, Motivation, Cannabis, RN, Knowledge, Racism, Path, NIH, Empowerment, Conference, Safety, Drug, MD, Psychedelic drug

2023 Portland Show Features Interactive Off-Site Event at ChemHistory, Oregon’s Premier Compliance Laboratory, in an Immersive Full Day Experience Prior to ConferencePORTLAND, OR, April 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Cannabis Science Conference (“CSC”), the premier cannabis science conference event focusing on analytical science, medical cannabis, cultivation, and psychedelics, announced today their pre-conference off-site workshop, Canna Boot Camp, taking place April 19 at ChemHistory, a quality control testing laboratory located in Milwaukie, Oregon.

Key Points: 
  • Canna Boot Camp is CSC’s full-day off-site workshop covering a wide range of cannabis science topics including cultivation, pre-processing, sample prep, analytical testing, extraction, and manufacturing.
  • CSC brings together industry experts to educate attendees in an interactive, workshop setting, located off-site from the conference the day before the show.
  • Canna Boot Camp attendees will rotate through interactive educational zones at ChemHistory, and gain a full understanding of how the cannabis industry works from seed to sale.
  • Canna Boot Camp is always well-attended by those seeking a greater understanding of cannabis science, for all skill levels.

Science-Forward Skincare Brand A.P. CHEM® Debuts New Age-Decelerating Products and Stigma-Breaking Social Campaign

Retrieved on: 
Tuesday, April 11, 2023
Mental Health, Millennials, Philanthropy, Alternative Medicine, Consumer, Health, Cosmetics, Generation X, Foundation, Retail, Psychedelic treatments for trauma-related disorders, GABA, Interior design, Autoimmunity, Gen, Inflammation, Hairdresser, Overalls, PTSD, CHEM, Multimedia, Classic, Veteran, Psychedelic drug, Judgement, Ketamine, Xennials, Collection, Serum, Diagnosis, Entrepreneurship, Mental health, Skin, Pharmaceutical industry

CHEM announces the launch of their newest age-decelerating skincare aimed at the Xennial and Gen X community that is both results-driven and accessibly priced.

Key Points: 
  • CHEM announces the launch of their newest age-decelerating skincare aimed at the Xennial and Gen X community that is both results-driven and accessibly priced.
  • CHEM combines the best of classic ingredients with clinically-proven Alt-Pharma™ ingredients to create a power-packed regimen.
  • “Our brand ethos is unique in its advocacy for Psychedelic Medicine because of my personal experience and connection to the cause.
  • CHEM and the “We See You” campaign, please visit www.apchembeauty.com and follow on Instagram at @apchembeauty .

PSYC’s CEO to Moderate Panel at Film Screening for ESPN’s Upcoming Documentary, "Peace of Mind"

Retrieved on: 
Wednesday, March 29, 2023
Psilocybin, ESPN, OTC Markets Group, Perelman School of Medicine at the University of Pennsylvania, NFL, Human, Road, Drug development, University, Cooper University Hospital, Friends, PPC, Policy, Pathology, NHL, Mind, Research, TBI, Psychedelic drug, Peace of Mind, Eventbrite, Traumatic brain injury, Pain management, Neurology, News, Nightclub, Nursing, Hope

Following the film screening, the PPC will host a panel discussion with experts in the fields of neurology, TBI research, psychedelic-assisted therapy, and policy moderated by David Flores.

Key Points: 
  • Following the film screening, the PPC will host a panel discussion with experts in the fields of neurology, TBI research, psychedelic-assisted therapy, and policy moderated by David Flores.
  • Moreover, the film examines the promising results of psychedelic-assisted therapy and its potential as a viable treatment for these debilitating conditions.
  • A second screening event will also be held on Wednesday April 26th at Cooper University Health Care.
  • Information and tickets for the Cooper University Health Care screening event may be found at the link below:

Cannabis Science Conference Returns to Portland, OR, With Renewed Focus on Analytical, Medical, Cultivation, and Psychedelic Scientific Insights

Retrieved on: 
Monday, March 13, 2023
Psilocybin, Analytic, Conference, Medical cannabis, University, Quality assurance, Education, Hemp, Empowerment, Veteran, Food, DO, OR, Sweet spot, Knowledge, Medicine, CSC, Editorial, Path, Track, Cannabinoid, Drug, MD, Cultivation, SRI, Safety, Psychedelic drug, Cannabis

PORTLAND, OR, March 13, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Cannabis Science Conference (“CSC”), the premier cannabis science conference event focusing on analytical science, medical cannabis, cultivation, and psychedelics, announced today the return of their groundbreaking event to Portland, Oregon from April 19-21 2023, a location which is perfectly positioned as a hotbed of cannabis activity and interest, and the epicenter of the new and emerging psychedelic market. 

Key Points: 
  • “Portland, Oregon is a natural fit for our Spring 2023 Cannabis Science Conference, with its established cannabis and medical markets, and openness toward emerging markets such as  psychedelics,” said Megan L’Heureux, spokesperson for CSC, and the group editorial director of Cannabis Science and Technology and Cannabis Patient Care magazines.
  • “CSC’s goal is to spread information and empowerment through education, and we are bringing a hard-hitting team of professional experts to share knowledge and have in-depth conversations about how to move these niche industries forward.
  • We look forward to tackling topics like using psychedelics and medical cannabis to help veterans and other patient demographics as well as our core  topic areas focused on analytical testing and cultivation.
  • The show will feature several key sessions, including:
    Low and Ultra-Low Doses of Cannabinoids: Are We Missing the Sweet Spot?

KCSA Strategic Communications Chosen as Agency of Record (AOR) for Psychedelic Science 2023, the Largest Gathering of Psychedelic Professionals in the Country, Sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS)

Retrieved on: 
Monday, March 13, 2023
Research, AOR, PTSD, Culture, Patient, FDA, Psychedelic drug, Science, KCSA, Nightclub, Pharmaceutical industry, Momentum

NEW YORK, March 13, 2023 /PRNewswire/ -- Psychedelic Science 2023 (PS2023), the largest event focused on the intersection of science, culture and business of psychedelics, announced it has selected KCSA Strategic Communications as its public relations agency of record (AOR).

Key Points: 
  • NEW YORK, March 13, 2023 /PRNewswire/ -- Psychedelic Science 2023 (PS2023), the largest event focused on the intersection of science, culture and business of psychedelics, announced it has selected KCSA Strategic Communications as its public relations agency of record (AOR).
  • Since 2018, KCSA Strategic Communications has had a dedicated psychedelics practice and will work with Momentum Events , to draw attention to the event and manage the on-site media relations.
  • "We have worked with Lewis and his team on psychedelic events and knew then that they were the right strategic communications partner for us to help manage the process for Psychedelic Science 2023."
  • If you are interested in attending Psychedelic Science 2023, KCSA is offering a 15% off discount code.

2023 SXSW Conference Hosts Psychedelic Healthcare VC Fund Palo Santo

Retrieved on: 
Thursday, March 9, 2023
Psilocybin, Fantastic Fungi, Psychiatry, Austin Convention Center, DSM-IV codes, Depression, Texas Tech University Health Sciences Center, MDMA, Netflix, Fungus, Private sector, Research, FDA, Internet, Science, Consciousness, SXSW, Book, MAPS, Pharmacology, Neuroscience, Traction, Hamilton Morris, Woman, PTSD, Music, Chronic pain, Doctor of Philosophy, Nightclub, Psychedelic drug, Ketamine, MD, Palo santo

Palo Santo , a venture capital fund focused on emerging psychedelic healthcare market, announced it will participate in several SXSW Psychedelics Tracks including:

Key Points: 
  • Palo Santo , a venture capital fund focused on emerging psychedelic healthcare market, announced it will participate in several SXSW Psychedelics Tracks including:
    Featured Session: To Trip or Not to Trip : Saturday, March 11, 2023 11:30 a.m. to 12:30 p.m. CT at the Austin Convention Center in Room 16AB – Join some of the leading researchers who will share their perspectives on the future of psychedelic science.
  • Those with decades of experience have knowledge that is crucial to finding the right paths forward as psychedelics go mainstream.
  • The psychedelic science torch is getting passed to the next generation, with fresh perspectives on both ancient and future medicines.
  • Sinai) and Palo Santo Cofounder Tim Schlidt explore the future of psychedelic science.

Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Retrieved on: 
Wednesday, March 8, 2023
Professional Services, Mental Health, Health, Finance, Pharmaceutical, Biotechnology, Conference, Webcast, Inc., NEO, NYSE, Psychedelic drug, Event, Pharmaceutical industry, Broadcasting, Auction

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics® is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a virtual fireside chat at the Oppenheimer 33rd Annual Healthcare Conference taking place on March 13-15, 2023.

Key Points: 
  • Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics® is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a virtual fireside chat at the Oppenheimer 33rd Annual Healthcare Conference taking place on March 13-15, 2023.
  • Mr. Drysdale’s fireside chat will be webcast live on Tuesday, March 14, 2023 at 12:40 p.m.
  • To listen to the event, please click here to access the webcast.
  • The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.

Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference

Retrieved on: 
Thursday, March 2, 2023
Alternative Medicine, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, NYSE, Ethnomedicine, Austin Convention Center, Consciousness, Multidisciplinary Association for Psychedelic Studies, Uday Chopra, CT, SXSW, Mind, Mental health, Conference, Interdisciplinarity, Open Mind, Psychedelic drug, MAPS, NEO, Inc., Pharmaceutical industry, Kernel

The panel titled, Open Minds: Innovations in Consciousness, Psychedelics & Mental Health, will be held on Sunday, March 12, 2023 at 11:30am CT at the Austin Convention Center.

Key Points: 
  • The panel titled, Open Minds: Innovations in Consciousness, Psychedelics & Mental Health, will be held on Sunday, March 12, 2023 at 11:30am CT at the Austin Convention Center.
  • For more information on SXSW and the featured panel, please click here .
  • As humanity begins to understand the complexity of consciousness and its impact on mental health, these worlds will become increasingly intertwined.
  • Open Minds will be released on April 19, 2023 on all smart devices everywhere and at www.altrd.tv .

PharmAla Biotech named Exclusive MDMA Supply Partner to Awakn Life Sciences

Retrieved on: 
Thursday, March 2, 2023
API, GMP, GLP, Psychedelic drug, Research, MDMA, Risk, Probability, CSE, Pharmaceutical industry, MDXX

VANCOUVER, British Columbia, March 02, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA), a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules (including MDMA) are pleased to announce that PharmAla has been named the exclusive MDMA supplier to Awakn LS Europe Holdings Limited (“Awakn”) (CSE:AWKN).

Key Points: 
  • VANCOUVER, British Columbia, March 02, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA), a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules (including MDMA) are pleased to announce that PharmAla has been named the exclusive MDMA supplier to Awakn LS Europe Holdings Limited (“Awakn”) (CSE:AWKN).
  • “Awakn and PharmAla share a bit of founding history – Prof. David Nutt, who was a founding board member of PharmAla, left our board in order to take on the role of Chief Research Officer of Awakn.
  • We think it’s completely fitting that we are able to supply Awakn with both engineering-grade and GMP LaNeo MDMA, which will grow their development program.
  • I look forward to continued collaboration with Anthony and the Awakn team.”
    Anthony Tennyson, CEO of Awakn commented, “We are pleased to have selected PharmAla as the exclusive GLP and GMP MDMA supplier for our MDMA research and development program.